SCHEMBL4095137

SCHEMBL4095137

FC(F)(F)c1ccc(-c2nc(N3CCCC3)c3ccccc3n2)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACP1 P24666 2/20 0.74
TSHR P16473 3/20 0.71
MEN1 O00255 2/20 0.71
KMT2A Q03164 2/20 0.71
USP2 O75604 2/20 0.71
LMNA P02545 4/20 0.70
MAPT P10636 2/20 0.70
GBA1 P04062 3/20 0.67
TLR7 Q9NYK1 1/20 0.63
RAB9A P51151 1/20 0.61
TP53 P04637 2/20 0.60
ABCG2 Q9UNQ0 1/20 0.59
ALDH1A1 P00352 2/20 0.58
MAPK1 P28482 2/20 0.58
NPSR1 Q6W5P4 1/20 0.58
HSD17B10 Q99714 1/20 0.58
HIF1A Q16665 1/20 0.57
HTT P42858 1/20 0.56
KDM4E B2RXH2 1/20 0.56
ABCB1 P08183 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4090807 0.99 ACP1 (0.75) ACP1TSHRMEN1KMT2AUSP2
SCHEMBL4085139 0.89 RAB9A (0.78) ACP1TSHRMEN1KMT2AUSP2
SCHEMBL4091461 0.89 HTT (0.73) ACP1TSHRMEN1KMT2AUSP2
SCHEMBL4096150 0.87 MEN1 (0.80) ACP1TSHRMEN1KMT2AUSP2
SCHEMBL4089260 0.86 ACP1 (1.00) ACP1TSHRMEN1KMT2AUSP2
SCHEMBL4092367 0.86 KMT2A (0.78) ACP1TSHRMEN1KMT2AUSP2
SCHEMBL1084210 0.85 ACP1 (0.81) ACP1TSHRMEN1KMT2AUSP2
SCHEMBL1083859 0.84 ACP1 (1.00) ACP1TSHRMEN1KMT2AUSP2
SCHEMBL1084122 0.84 ACP1 (1.00) ACP1TSHRMEN1KMT2AUSP2
SCHEMBL1084295 0.84 ACP1 (0.81) ACP1TSHRMEN1KMT2AUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
WO-2008157500-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2008-12-24 WO disclosed
WO-2008157500-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2008-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE CNR2, CNR1, GPR18 ACP1 3504/4885TSHR 3396/4885MEN1 718/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.